BioLineRx Ltd. (NASDAQ:BLRX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Monday.

According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “

Other analysts also recently issued reports about the company. HC Wainwright set a $4.00 target price on BioLineRx and gave the company a “buy” rating in a research note on Saturday, June 3rd. Oppenheimer Holdings, Inc. began coverage on BioLineRx in a research note on Friday, August 4th. They issued an “outperform” rating and a $3.00 price target on the stock. Roth Capital set a $3.00 price target on BioLineRx and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Maxim Group upgraded BioLineRx from a “hold” rating to a “buy” rating and raised their price target for the stock from $1.00 to $3.00 in a research note on Thursday, May 18th. Finally, ValuEngine upgraded BioLineRx from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. BioLineRx currently has an average rating of “Buy” and a consensus target price of $2.59.

Shares of BioLineRx (NASDAQ:BLRX) traded up 0.85% during trading on Monday, hitting $1.18. The company had a trading volume of 528,685 shares. The stock has a 50-day moving average of $0.96 and a 200 day moving average of $0.97. The stock’s market capitalization is $112.83 million. BioLineRx has a 12-month low of $0.80 and a 12-month high of $1.42.

BioLineRx (NASDAQ:BLRX) last issued its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.05) EPS for the quarter, meeting the consensus estimate of ($0.05). On average, analysts predict that BioLineRx will post ($0.24) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/14/biolinerx-ltd-nasdaqblrx-stock-rating-lowered-by-zacks-investment-research.html.

A number of institutional investors have recently made changes to their positions in the company. Benchmark Capital Advisors boosted its position in shares of BioLineRx by 227.3% in the first quarter. Benchmark Capital Advisors now owns 144,000 shares of the biotechnology company’s stock worth $138,000 after buying an additional 100,000 shares in the last quarter. Citadel Advisors LLC boosted its position in shares of BioLineRx by 443.4% in the first quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock worth $102,000 after buying an additional 86,481 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of BioLineRx during the first quarter worth approximately $126,000. KCG Holdings Inc. boosted its position in shares of BioLineRx by 715.9% in the first quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock worth $168,000 after buying an additional 153,687 shares in the last quarter. Finally, Sabby Management LLC bought a new position in shares of BioLineRx during the first quarter worth approximately $3,018,000. 34.98% of the stock is currently owned by institutional investors.

About BioLineRx

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

Get a free copy of the Zacks research report on BioLineRx (BLRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for BioLineRx (NASDAQ:BLRX)

Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.